Subsequently, we evaluated the prognostic accuracy of CCNB2, CDC20 and MYBL2 by calculating the time‐dependent ROC, AUC (area under the ROC curve) for one‐, three‐ and five‐year survival in glioma patients. This evidence concerns the gene MYBL2 and central nervous system cancer.